Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EBIT (2022 - 2025)

Historic EBIT for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$36.1 million.

  • Century Therapeutics' EBIT fell 383.74% to -$36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.9 million, marking a year-over-year increase of 7656.12%. This contributed to the annual value of -$138.1 million for FY2024, which is 573.81% up from last year.
  • Per Century Therapeutics' latest filing, its EBIT stood at -$36.1 million for Q3 2025, which was down 383.74% from -$34.7 million recorded in Q2 2025.
  • Century Therapeutics' 5-year EBIT high stood at $74.2 million for Q1 2025, and its period low was -$43.8 million during Q4 2023.
  • Over the past 4 years, Century Therapeutics' median EBIT value was -$34.8 million (recorded in 2024), while the average stood at -$27.7 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 3139.37% in 2023, then skyrocketed by 33691.59% in 2025.
  • Century Therapeutics' EBIT (Quarter) stood at -$33.3 million in 2022, then crashed by 31.39% to -$43.8 million in 2023, then grew by 14.8% to -$37.3 million in 2024, then increased by 3.11% to -$36.1 million in 2025.
  • Its EBIT was -$36.1 million in Q3 2025, compared to -$34.7 million in Q2 2025 and $74.2 million in Q1 2025.